Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Woodford Debacle Is A Test of UK Biotech’s Resilience

Mon, 10/14/2019 - 1:16pm

As once-star investment funds continue to weaken, another major investor argues this is opportunity for UK biotech to demonstrate staying...

      Related Stories 

Novo Nordisk, Bluebird Targeting ‘Lifelong’ Gene Therapies

Mon, 10/14/2019 - 12:29pm

Novo Nordisk and bluebird bio will jointly develop genome editing treatments for genetic diseases, beginning with hemophilia.

      Related Stories 

Pipeline Watch: Phase III Starts With Lebrikizumab, Beperminogene

Mon, 10/14/2019 - 2:57am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis

Sun, 10/13/2019 - 7:52am

The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par...

      Related Stories 

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

Fri, 10/11/2019 - 2:13pm

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public...

      Related Stories 

Lilly Expands Migraine Franchise With Reyvow Approval

Fri, 10/11/2019 - 2:09pm

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the...

      Related Stories 

Interview: Akari's Coversin Ticking Along Nicely

Fri, 10/11/2019 - 10:56am

The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he...

      Related Stories 

Pharma Will Embrace Basket And Umbrella Trials, Despite Challenges

Fri, 10/11/2019 - 10:33am

New approaches in study design and methodology, including master protocol trials, are being adopted by biopharma.

      Related Stories 

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

Fri, 10/11/2019 - 7:42am

The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi...

      Related Stories 

MolMed Pulls Zalmoxis Cell Therapy In EU

Fri, 10/11/2019 - 6:57am

The Italian biotech will redirect investment, initially reserved for Zalmoxis, to other activities that would better meet its business objectives.

      Related Stories 

BioNTech Falls Short In Jittery IPO Market

Thu, 10/10/2019 - 11:16pm

After ADC Therapeutics postponed its launch last week, BioNTech braves the markets but finds them less receptive than hoped.

      Related Stories 

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

Thu, 10/10/2019 - 2:08pm

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC...

      Related Stories 

Bayer/Ionis Advance Next-Generation Antithrombotic After Positive Clinical Results

Thu, 10/10/2019 - 6:49am

In a collaboration with Ionis Pharmaceuticals, Bayer is pressing ahead with Phase II clinical studies of an antisense molecule designed...

      Related Stories 

Executives On The Move: New Leaders Fill C-Suite Positions At Midatech, Retrophin And Sangamo

Thu, 10/10/2019 - 2:02am

Midatech Pharma and Retrophin – both developing therapies for rare diseases – appoint CFO and chief commercial officer, respectively. Meanwhile...

      Related Stories 

Gilead’s New O’Day Regime Has New R&D Structure

Wed, 10/09/2019 - 8:00pm

After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum. 

      Related Stories 

Clinuvel Completes Arduous Journey To US Approval Of Scenesse

Wed, 10/09/2019 - 1:48pm

First-in-class drug for rare disease EPP obtains FDA approval, company plans treatment center-based rollout. Scenesse, on the market in Europe...

      Related Stories